Ame Company For Medical Supplies (9527.SR) — Income statement
Revenue, gross profit, operating income, net income, and EPS for Ame Company For Medical Supplies — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 305↑22.8% | 248↑11.2% | 223↑15.6% | 193↑27.6% | 151 | |
| Cost of Revenue | 176↑19.2% | 148↑18.8% | 125↑21.1% | 103↑25.7% | 82 | |
| Gross Profit | 128↑28.1% | 100↑1.6% | 99↑9.4% | 90↑29.8% | 70 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 0.00↓100.0% | 17↑476.0% | 3↓55.2% | 7↑43.8% | 5 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 41↑20.4% | 34↑14.9% | 30↑25.7% | 24 | |
| SG&A Expenses | 0.00↓100.0% | 55↑48.2% | 37↑2.4% | 36↑28.6% | 28 | |
| Other Expenses | 86↑2160.7% | -4↓117.1% | 24↑1.2% | 24↑43.0% | 17 | |
| Operating Expenses | 86↑67.7% | 51↓17.0% | 61↑1.9% | 60↑33.9% | 45 | |
| Total Costs & Expenses | 262↑31.7% | 199↑7.0% | 186↑14.0% | 163↑28.6% | 127 | |
| Operating Results | ||||||
| Operating Income | 43↓13.0% | 49↑32.2% | 37↑24.4% | 30↑22.3% | 25 | |
| Depreciation & Amortization | 0.00↓100.0% | 2↑18.9% | 2↑79.9% | 0.85↑86.0% | 0.46 | |
| EBITDA | 43↓17.6% | 52↑32.3% | 39↑26.9% | 31↑24.8% | 25 | |
| EBIT | 43↓14.6% | 50↑32.9% | 38↑25.4% | 30↑23.2% | 24 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↑100.0% | -0.17↑73.8% | -0.65↓87.4% | -0.35↓40.8% | -0.25 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 0.17↓73.8% | 0.65↑87.4% | 0.35↑40.8% | 0.25 | |
| Non-Operating Income | 0.00↑100.0% | -0.91↓302.3% | 0.45↑377.1% | -0.16↓383.5% | 0.06 | |
| Other Income / Expenses | -43↓17034.8% | 0.25↓14.7% | 0.30↑415.1% | 0.06↑118.9% | -0.30 | |
| Income Before Tax | 0.00↓100.0% | 50↑33.2% | 38↑25.1% | 30↑24.1% | 24 | |
| Income Tax Expense | 0.00↓100.0% | 5↑14.1% | 4↑21.5% | 3↑12.1% | 3 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 0.00↓100.0% | 45↑35.5% | 34↑25.6% | 27↑25.7% | 21 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 35↓22.9% | 45↑35.5% | 34↑25.6% | 27↑25.7% | 21 | |
| Bottom-Line Net Income | 35↓22.9% | 45↑35.5% | 34↑25.6% | 27↑25.7% | 21 | |
| EPS (Basic) | 5.00↓23.0% | 6.49↑35.5% | 4.79↑25.7% | 3.81↑24.9% | 3.05 | |
| EPS (Diluted) | 5.00↓23.0% | 6.49↑35.5% | 4.79↑25.7% | 3.81↑24.9% | 3.05 | |
| Weighted Average Shares | 7↑0.0% | 7↑0.0% | 7↑0.0% | 7↑0.6% | 7 | |
| Weighted Average Diluted Shares | 7↑0.0% | 7↑0.0% | 7↑0.0% | 7↑0.6% | 7 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.